Rigaku Raman Upgrades Handheld Analyzer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Rigaku Raman Upgrades Handheld Analyzer


Rigaku Raman Technologies announced an updated version of the FirstGuard handheld Raman analyzer at Pittcon 2013. The analyzer operates at 1064 nm wavelength, enabling it to identify a broader range of raw materials and provide very rapid validation in comparison to 785 nm wavelength excitation products. Features include an integrated bar code reader enabling for GMP Raw Material Identification applications, user account management, upgraded data reporting and archiving, and improved data and operator security to support integration into FDA regulated manufacturing environments, the company reports. The analyzer is equipped with an integrated vial holder and hot swappable lithium ion battery, and is configured with secure software for 21 CRF part 11 compliance.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here